Literature DB >> 24072678

Resolvin D1 improves survival in experimental sepsis through reducing bacterial load and preventing excessive activation of inflammatory response.

F Chen1, X H Fan, Y P Wu, J L Zhu, F Wang, L L Bo, J B Li, R Bao, X M Deng.   

Abstract

Sepsis is characterized as an uncontrolled inflammatory response. Spite et al. (Nature 461(7268):1287-1291, 2009) had demonstrated that resolvin D2, which is derived from docosahexaenoic acid (DHA), improves survival in cecal ligation and puncture (CLP)-initiated sepsis and enhances bacterial clearance without immune suppression. Resolvin D1, which is also derived from DHA and homologous with resolvin D2, is an endogenous anti-inflammatory and proresolving lipid molecule. We sought to investigate the effects of resolvin D1 on sepsis and to explore the mechanism of action. Six-to-eight-week-old male C57BL/6 mice were randomly divided into three groups: the sham group underwent the sham operation followed by tail vein injection of vehicle (0.1 % ethanol); the CLP group received vehicle (0.1 % ethanol) after CLP; the resolvin D1 group received resolvin D1 (100 ng) after CLP. Blood, peritoneal lavage fluid, and organs of mice were harvested 24 h after treatment for cytokine analysis, cell counts, bacterial cultures, histopathological studies, and apoptosis quantification. Compared with the vehicle control group, the survival rate and bacterial clearance of mice with sepsis induced by CLP were improved after resolvin D1 treatment, but the numbers of neutrophils in peritoneal lavage fluid, the inflammatory cytokines, the phosphorylation of the nuclear factor-κB (NF-κB) (P65) pathway, and the apoptosis rate of CD3(+) T lymphocytes of the thymus were suppressed. Resolvin D1 treatment improved survival in mice with sepsis induced by CLP, enhanced organism bacterial clearance, suppressed the increase of the numbers of neutrophils in peritoneal lavage fluid, reduced the release of inflammatory cytokines, and decreased the apoptosis rate of CD3(+) T lymphocytes of the thymus. These results suggest that resolvin D1 may attenuate the degree of inflammatory reaction in sepsis caused by CLP, without harming the host defense response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24072678     DOI: 10.1007/s10096-013-1978-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  33 in total

1.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes.

Authors:  Jan M Schwab; Nan Chiang; Makoto Arita; Charles N Serhan
Journal:  Nature       Date:  2007-06-14       Impact factor: 49.962

2.  Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects.

Authors:  Thomas-Thi Pluess; Daniel Hayoz; Mette M Berger; Luc Tappy; Jean-Pierre Revelly; Burkhard Michaeli; Yvon A Carpentier; René L Chioléro
Journal:  Intensive Care Med       Date:  2007-03-22       Impact factor: 17.440

Review 3.  Prevention of lymphocyte apoptosis--a potential treatment of sepsis?

Authors:  Richard S Hotchkiss; Craig M Coopersmith; Irene E Karl
Journal:  Clin Infect Dis       Date:  2005-11-15       Impact factor: 9.079

4.  Immunodesign of experimental sepsis by cecal ligation and puncture.

Authors:  Daniel Rittirsch; Markus S Huber-Lang; Michael A Flierl; Peter A Ward
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

5.  Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation.

Authors:  Driss El Kebir; Per Gjorstrup; János G Filep
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

Review 6.  Innate immunity in sepsis pathogenesis and its modulation: new immunomodulatory targets revealed.

Authors:  V Kumar; A Sharma
Journal:  J Chemother       Date:  2008-12       Impact factor: 1.714

7.  Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003.

Authors:  Viktor Y Dombrovskiy; Andrew A Martin; Jagadeeshan Sunderram; Harold L Paz
Journal:  Crit Care Med       Date:  2007-05       Impact factor: 7.598

8.  Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators.

Authors:  Aksam J Merched; Kerry Ko; Katherine H Gotlinger; Charles N Serhan; Lawrence Chan
Journal:  FASEB J       Date:  2008-06-17       Impact factor: 5.191

9.  Severity of sepsis is correlated with the elevation of serum high-mobility group box 1 in rats.

Authors:  Li-chao Hou; Ming-zhe Qin; Li-na Zheng; Yan Lu; Qiang Wang; Dao-rong Peng; Xin-ping Yu; Yu-chang Xin; Gen-lin Ji; Li-ze Xiong
Journal:  Chin Med J (Engl)       Date:  2009-02-20       Impact factor: 2.628

10.  Infection regulates pro-resolving mediators that lower antibiotic requirements.

Authors:  Nan Chiang; Gabrielle Fredman; Fredrik Bäckhed; Sungwhan F Oh; Thad Vickery; Birgitta A Schmidt; Charles N Serhan
Journal:  Nature       Date:  2012-04-25       Impact factor: 49.962

View more
  30 in total

1.  Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes.

Authors:  Zhen Gu; Gwyneth J Lamont; Richard J Lamont; Silvia M Uriarte; Huizhi Wang; David A Scott
Journal:  Innate Immun       Date:  2016-02-15       Impact factor: 2.680

2.  Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection.

Authors:  M Codagnone; E Cianci; A Lamolinara; V C Mari; A Nespoli; E Isopi; D Mattoscio; M Arita; A Bragonzi; M Iezzi; M Romano; A Recchiuti
Journal:  Mucosal Immunol       Date:  2017-04-19       Impact factor: 7.313

3.  Resolvin D1 Attenuates Innate Immune Reactions in Experimental Subarachnoid Hemorrhage Rat Model.

Authors:  Guang-Jie Liu; Tao Tao; Xiang-Sheng Zhang; Yue Lu; Ling-Yun Wu; Yong-Yue Gao; Han Wang; Hai-Bin Dai; Yan Zhou; Zong Zhuang; Chun-Hua Hang; Wei Li
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

Review 4.  Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.

Authors:  Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 5.  Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.

Authors:  Melissa Gabbs; Shan Leng; Jessay G Devassy; Md Monirujjaman; Harold M Aukema
Journal:  Adv Nutr       Date:  2015-09-15       Impact factor: 8.701

6.  Dietary Omega-3 Fatty Acids Increase Survival and Decrease Bacterial Load in Mice Subjected to Staphylococcus aureus-Induced Sepsis.

Authors:  Sara L Svahn; Marcus A Ulleryd; Louise Grahnemo; Marcus Ståhlman; Jan Borén; Staffan Nilsson; John-Olov Jansson; Maria E Johansson
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

7.  Protective actions of aspirin-triggered (17R) resolvin D1 and its analogue, 17R-hydroxy-19-para-fluorophenoxy-resolvin D1 methyl ester, in C5a-dependent IgG immune complex-induced inflammation and lung injury.

Authors:  Huifang Tang; Yanlan Liu; Chunguang Yan; Nicos A Petasis; Charles N Serhan; Hongwei Gao
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

8.  Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages.

Authors:  Amanda Croasdell; Thomas H Thatcher; R Matthew Kottmann; Romain A Colas; Jesmond Dalli; Charles N Serhan; Patricia J Sime; Richard P Phipps
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-21       Impact factor: 5.464

9.  Resolvin D2 decreases TLR4 expression to mediate resolution in human monocytes.

Authors:  Amanda Croasdell; Patricia J Sime; Richard P Phipps
Journal:  FASEB J       Date:  2016-06-02       Impact factor: 5.191

10.  Resolvin D1 Promotes SIRT1 Expression to Counteract the Activation of STAT3 and NF-κB in Mice with Septic-Associated Lung Injury.

Authors:  Yuzhen Zhuo; Shukun Zhang; Caixia Li; Lei Yang; Hongwei Gao; Ximo Wang
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.